» Articles » PMID: 21540571

Evolving Pattern with Age of Cutaneous Signs in Neurofibromatosis Type 1: a Cross-sectional Study of 728 Patients

Overview
Journal Dermatology
Publisher Karger
Specialty Dermatology
Date 2011 May 5
PMID 21540571
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Neurofibromatosis type 1 is fully penetrant by the age of 8 years, and 3 criteria of diagnosis are dermatological: café-au-lait spots (CLS), intertriginous freckling and neurofibromas (NF).

Objectives: The aim of our study was to determine the evolving pattern of cutaneous manifestations during adulthood.

Methods: Phenotypic data of patients seen in our center between March 2003 and December 2009 were studied. Patients were classified in 10-year groups. Following clinical characteristics, the number of CLS and the number of cutaneous and subcutaneous NF were compared according to age.

Results: 728 subjects, 404 females and 324 males (mean age of 32.4 years, range 6-80 years) were studied. Four hundred eighty-nine patients were over 20 years old (67%). The number of CLS (small or large) was significantly decreased with age while the number of cutaneous and subcutaneous NF was strongly increased (p < 0.001).

Conclusions: The decrease in CLS with age has not been previously reported while an increase in the number of NF is well described during puberty and pregnancy and with age.

Citing Articles

Pregnancy and the Risk for Cancer in Neurofibromatosis 1.

Kallionpaa R, Maattanen J, Leppavirta J, Peltonen S, Peltonen J Genes Chromosomes Cancer. 2025; 64(2):e70017.

PMID: 39985314 PMC: 11846020. DOI: 10.1002/gcc.70017.


Examining Demographic and Clinical Traits in Neurofibromatosis Type 1 Patients: Insights into Vitamin D Levels and Connections with Nevus Anemicus and Neurofibromas.

Ahmadi V, Karimi N, Evans A, Karaduman A Indian J Dermatol. 2025; 70(1):11-17.

PMID: 39896307 PMC: 11784969. DOI: 10.4103/ijd.ijd_141_24.


Sonographic Characterization of Red-Blue Neurofibromas in Patients With Neurofibromatosis Type 1: An Observational Prospective Study.

Oteiza-Rius I, Estenaga Perez de Albeniz A, Hernandez-Martin A, Alfageme Roldan F, Garcia-Martinez F J Ultrasound Med. 2024; 44(4):703-709.

PMID: 39665148 PMC: 11892087. DOI: 10.1002/jum.16632.


Diagnosis and management of neurofibromatosis type 1 in Arabian Gulf Cooperation Council Region: challenges and recommendations.

Bashiri F, Hundallah K, Abukhaled M, Alyahya M, Al Futaisi A, Alshowaeir D Front Oncol. 2024; 14:1323176.

PMID: 39257551 PMC: 11385870. DOI: 10.3389/fonc.2024.1323176.


Real-world Settings for the Surgical Treatment of Neurofibroma in Patients with Neurofibromatosis Type 1.

Ota M, Nobeyama Y, Asahina A JMA J. 2024; 7(2):205-212.

PMID: 38721077 PMC: 11074565. DOI: 10.31662/jmaj.2023-0161.